GPR35 and metabolic dysfunction-associated steatotic liver disease: While previous studies have implicated GPR35 in the context of metabolic dysfunction-associated steatotic liver disease (MASLD) and MASH [9–12], its precise function in fatty liver disease and how it modulates metabolism in specific liver zones remain to be fully characterized.